

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

December 31, 2020

	Shares	Value
COMMON STOCKS[†] - 99.6%		
Biotechnology - 72.9%		
Amgen, Inc.	46,124	\$ 10,604,830
Gilead Sciences, Inc.	137,327	8,000,671
Vertex Pharmaceuticals, Inc.*	30,030	7,097,290
Illumina, Inc.*	18,293	6,768,410
Regeneron Pharmaceuticals, Inc.*	13,496	6,520,053
Biogen, Inc.*	22,700	5,558,322
Moderna, Inc.*	49,814	5,204,069
Corteva, Inc.	125,161	4,846,234
Alexion Pharmaceuticals, Inc.*	30,030	4,691,887
Seagen, Inc.*	26,529	4,646,289
Exact Sciences Corp.*	31,204	4,134,218
Incyte Corp.*	44,634	3,882,265
Bio-Rad Laboratories, Inc. — Class A*	6,450	3,759,963
BioMarin Pharmaceutical, Inc.*	38,909	3,411,930
Alnylam Pharmaceuticals, Inc.*	25,838	3,358,165
Guardant Health, Inc.*	25,656	3,306,545
Mirati Therapeutics, Inc.*	13,253	2,910,889
Ionis Pharmaceuticals, Inc.*	48,279	2,729,695
ACADIA Pharmaceuticals, Inc.*	49,103	2,625,046
CRISPR Therapeutics AG*	16,740	2,563,061
BeiGene Ltd. ADR*	9,710	2,508,967
Acceleron Pharma, Inc.*	18,632	2,383,778
Iovance Biotherapeutics, Inc.*	50,194	2,329,002
Arrowhead Pharmaceuticals, Inc.*	30,137	2,312,412
United Therapeutics Corp.*	15,148	2,299,315
BioNTech SE ADR ^{*,1}	27,800	2,266,256
Ultragenyx Pharmaceutical, Inc.*	16,339	2,261,808
Twist Bioscience Corp.*	15,850	2,239,446
Exelixis, Inc.*	111,104	2,229,857
Novavax, Inc. ^{*,1}	19,860	2,214,589
Amicus Therapeutics, Inc.*	95,070	2,195,166
Halozyme Therapeutics, Inc.*	50,560	2,159,418
Blueprint Medicines Corp.*	18,770	2,105,056
Fate Therapeutics, Inc.*	23,040	2,095,027
Sage Therapeutics, Inc.*	23,286	2,014,472
Biohaven Pharmaceutical Holding Company Ltd.*	22,920	1,964,473
Arena Pharmaceuticals, Inc.*	25,260	1,940,726
ChemoCentryx, Inc.*	30,270	1,874,318
PTC Therapeutics, Inc.*	29,928	1,826,506
Emergent BioSolutions, Inc.*	20,360	1,824,256
Bluebird Bio, Inc.*	36,415	1,575,677
Global Blood Therapeutics, Inc.*	34,845	1,509,137
Inovio Pharmaceuticals, Inc. ^{*,1}	125,840	1,113,684
Total Biotechnology Pharmaceuticals - 17.5%		143,863,178
AbbVie, Inc.	121,152	12,981,437
Viatis, Inc.*	241,037	4,517,033
Horizon Therapeutics plc*	53,015	3,878,047
Jazz Pharmaceuticals plc*	19,797	3,267,495
Sarepta Therapeutics, Inc.*	19,079	3,252,779
Neurocrine Biosciences, Inc.*	27,696	2,654,662
PRA Health Sciences, Inc.*	20,545	2,577,165
Pacira BioSciences, Inc.*	24,880	1,488,819
Total Pharmaceuticals		34,617,437
Healthcare-Products - 5.7%		
Bio-Techne Corp.	10,248	3,254,252
Novocure Ltd.*	17,763	3,073,710
Natera, Inc.*	24,900	2,478,048
Adaptive Biotechnologies Corp.*	41,050	2,427,286
Total Healthcare-Products		11,233,296
Healthcare-Services - 3.5%		
Invitae Corp. ^{*,1}	58,730	2,455,501
Syneos Health, Inc.*	35,650	2,428,835
Medpace Holdings, Inc.*	13,720	1,909,824
Total Healthcare-Services		6,794,160
Total Common Stocks (Cost \$98,761,794)		196,508,071
RIGHTS^{†††} - 0.0%		
Biotechnology - 0.0%		
Clinical Data, Inc.*	24,000	0
Total Rights (Cost \$—)		0
Face Amount		
REPURCHASE AGREEMENTS^{††,2} - 0.9%		
J.P. Morgan Securities LLC issued 12/31/20 at 0.06% due 01/04/21	\$ 969,572	969,572
Barclays Capital, Inc. issued 12/31/20 at 0.06% due 01/04/21	403,934	403,934
BofA Securities, Inc. issued 12/31/20 at 0.06% due 01/04/21	374,013	374,013
Total Repurchase Agreements (Cost \$1,747,519)		1,747,519
Shares		
SECURITIES LENDING COLLATERAL^{†,3} - 3.3%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 0.03% ⁴	6,591,834	6,591,834
Total Securities Lending Collateral (Cost \$6,591,834)		6,591,834
Total Investments - 103.8% (Cost \$107,101,147)	\$	204,847,424
Other Assets & Liabilities, net - (3.8)%		(7,432,775)
Total Net Assets - 100.0%	\$	197,414,649

* Non-income producing security.
[†] Value determined based on Level 1 inputs.
^{††} Value determined based on Level 2 inputs.
^{†††} Value determined based on Level 3 inputs.

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

December 31, 2020

-
- ¹ All or a portion of this security is on loan at December 31, 2020.
² Repurchase Agreements.
³ Securities lending collateral.
⁴ Rate indicated is the 7-day yield as of December 31, 2020.

ADR — American Depositary Receipt
plc — Public Limited Company